Iron Chelator Induces Apoptosis in Osteosarcoma Cells by Disrupting Intracellular Iron Homeostasis and Activating the MAPK Pathway
Osteosarcoma is a common malignant bone tumor in clinical orthopedics. Iron chelators have inhibitory effects on many cancers, but their effects and mechanisms in osteosarcoma are still uncertain. Our in vitro results show that deferoxamine (DFO) and deferasirox (DFX), two iron chelators, significan...
Main Authors: | Yanru Xue, Gejing Zhang, Shoujie Zhou, Shenghang Wang, Huanhuan Lv, Liangfu Zhou, Peng Shang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/13/7168 |
Similar Items
-
Importance of iron chelation therapy
by: A. Varoğlu
Published: (2011-12-01) -
Alterations in Cellular Iron Metabolism Provide More Therapeutic Opportunities for Cancer
by: Liangfu Zhou, et al.
Published: (2018-05-01) -
New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases
by: Marco T. Nuñez, et al.
Published: (2018-10-01) -
Deferasirox, an oral chelator in the treatment of iron overload
by: I. Portioli
Published: (2013-05-01) -
Comparison of Treatment Effects of Different Iron Chelators in Experimental Models of Sepsis
by: Christian Lehmann, et al.
Published: (2021-01-01)